Država: Izrael
Jezik: angleščina
Source: Ministry of Health
DAPTOMYCIN
MERCK SHARP & DOHME (ISRAEL - 1996) COMPANY LTD, ISRAEL
J01XX09
LYOPHILIZED POWDER FOR SOLUTION FOR INJECTION
DAPTOMYCIN 500 MG/VIAL
I.V
Required
MERCK SHARP & DOHME LLC, USA
DAPTOMYCIN
Cubicin is indicated for the treatment of the infections listed below. * Complicated Skin and Skin Structure InfectionsComplicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only).* Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant IsolatesStaphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates.* Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram negative or anaerobic organisms
2014-06-30
_ _ _ _ _ _ _אפורל ןולעב )תוחיטב עדימ ( הרמחה לע העדוה_ _אפורל ןולעב )תוחיטב עדימ ( הרמחה לע העדוה_ _אפורל ןולעב )תוחיטב עדימ ( הרמחה לע העדוה_ _ _ _ _ _ _ _ ןכדועמ(_ _ ןכדועמ(_ _ ןכדועמ(_ _.102.50_ _.102.50_ _.102.50_ _)_ _)_ _)_ _ _ _ _ _ _ ךיראת :ןולעה רושיא 61. 11 םושירה רפסמו תילגנאב רישכת םש 131 21 30994 01 : CUBICIN REG.NO םושירה לעב םש ISRAEL LTD. MERCK SHARP & DOHME פוט ! דבלב תורמחהה טורפל דעוימ הז ס תושקובמה תורמחהה ןולעב קרפ נ טסקט יחכו שדח טסקט 6.2 POST –MARKETING EXPERIENCE The following adverse reactions have been identified during postapproval use of CUBICIN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure. _Immune System Disorders:_ anaphylaxis; hypersensitivity reactions, including angioedema, drug rash with eosinophilia and systemic symptoms (DRESS), pruritus, hives, shortness of breath, difficulty swallowing, truncal erythema, and pulmonary eosinophilia [see _Contraindications (4), Warnings and Precautions _ _(5.1)_] _Infections and Infestations: Clostridium difficile_– associated diarrhea [see _Warnings and _ _Precautions (5.6)_] _Musculoskeletal Disorders:_ myoglobin increased; rhabdomyolysis (some reports involved patients treated concurrently with CUBICIN and HMG-CoA reductase inhibitors) [see _Warnings and Precautions (5.2), Drug _ _Interactions (7.1),_ and _Clinical Pharmacology _ _(12.3)_] _Respiratory, Thoracic, and Mediastinal _ _Disorders:_ cough, eosinophilic pneumonia [see _Warnings and Precautions (5.3)_] _Nervous System Disorders:_ peripheral neuropathy [see _Warnings and Precautions _ _(5.4)_] _Skin and Subcutaneous Tissue Disorders:_ serious skin reactions, including Stevens- Johnson syndrome and Preberite celoten dokument
1 PRESCRIBING INFORMATION Name of the medicinal p roduct : CUBICIN ® 500 MG Qualitative and qua ntitative composition : Cubicin 500 mg lyophilized powder for solution for injection . Each vial contains 500 mg da p tomycin as a sterile, lyophilized powder. 1 INDIC ATIONS AND USAGE CUBICIN is indicated for the t reatment of t he infections listed below . 1.1 COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS Complicated skin and skin structure infections (cSSSI) caused b y susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including m ethicillin-re sistant isolates), Streptococc us pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin- susceptible isolates only). 1.2 STAPHYLO COCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA ), INCLUDING THOSE WITH RIGHT- SIDED INFECTI VE ENDOCARDITIS, CAUSED BY METHICILLIN - SUSCEPTIBLE AND METHICILLIN - RESISTANT ISOLATES Staphylococcus aureus bloods tream infections (bacteremia), including those wi th right- sided infective endocarditis, caused by methicillin-s usceptible and methicillin -res istant isolates. Combination therapy may be clinically indicated if the documented or presumed pathogens include G ram negative or anaerobic organism . 1.3 LIMITATI ONS OF USE CUBICIN is not indicated for the tre atment of pn eumonia. CUBICIN is not indic ated for the treatment of left - sided infective endocarditis due to S. aureus . The clinical trial of CUBICIN in adult patients with S. aureus bloodstream infections in cluded limited data from patients with left -sided infective endocarditis; outcomes in the se patients were poor [see Clinical Studies (14.2)] . CUBICIN has not been studied in patients with prosthetic valve endocarditis. 1.4 USAGE Appropriate spe cimens for microbi ological examination should be obtained in order to isolate and identify t he causative pathogens and to determine their susceptibility to daptomycin. To reduce the development of drug -resistant b acteria and maint Preberite celoten dokument